Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 5/20 | 0.30 |
| ▸ | CNR1 | P21554 | 3/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10301894 | 0.93 | TUBB1 (0.38) | TUBB1MEN1KMT2A | |
| SCHEMBL10301892 | 0.92 | TUBB1 (0.36) | TUBB1TOP2ACNR2CNR1 | |
| SCHEMBL15495057 | 0.89 | TUBB1 (0.40) | TUBB1TOP2AALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL10301893 | 0.89 | TUBB1 (0.39) | TUBB1TOP2AMEN1KMT2A | |
| SCHEMBL12889220 | 0.88 | — | — | |
| SCHEMBL10301899 | 0.87 | TUBB1 (0.38) | TUBB1TOP2AMEN1KMT2A | |
| SCHEMBL12739036 | 0.86 | HDAC3 (0.31) | CNR2 | |
| SCHEMBL10301888 | 0.85 | MAOA (0.30) | — | |
| SCHEMBL14766307 | 0.85 | TUBB1 (0.38) | TUBB1TOP2AALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL12739042 | 0.85 | TUBB1 (0.38) | TUBB1TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | TUBB1 548/4885TOP2A 3093/4885ACE2 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.